This is not the most recent version of the article. View current version (12 JUN 2013)

Intervention Protocol

Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease

  1. Zbys Fedorowicz1,*,
  2. Esther J van Zuuren2,
  3. Amani Al Hajeri3

Editorial Group: Cochrane Cystic Fibrosis and Genetic Disorders Group

Published Online: 17 OCT 2012

Assessed as up-to-date: 2 NOV 2012

DOI: 10.1002/14651858.CD010155

How to Cite

Fedorowicz Z, van Zuuren EJ, Al Hajeri A. Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 10. Art. No.: CD010155. DOI: 10.1002/14651858.CD010155.

Author Information

  1. 1

    The Cochrane Collaboration, UKCC (Bahrain Branch), Awali, Bahrain

  2. 2

    Leiden University Medical Center, Department of Dermatology, Leiden, Netherlands

  3. 3

    Ministry of Health, Department of Genetics, Awali, Bahrain

*Zbys Fedorowicz, UKCC (Bahrain Branch), The Cochrane Collaboration, Box 25438, Awali, Bahrain. zbysfedorowicz@gmail.com. zbysfedorowicz@gmail.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 17 OCT 2012

SEARCH

This is not the most recent version of the article. View current version (12 JUN 2013)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the effects of LMWHs for managing vaso-occlusive crises in people with SCD.